{"id":"NCT03390166","sponsor":"Mahidol University","briefTitle":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","officialTitle":"A Phase II/III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 18-49 Years","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-07-24","primaryCompletion":"2018-03-31","completion":"2019-02-12","firstPosted":"2018-01-04","resultsPosted":"2020-04-14","lastUpdate":"2020-04-14"},"enrollment":945,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GPO Tri Fluvac vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Licensed influenza vaccine","otherNames":[]}],"arms":[{"label":"GPO Tri Fluvac vaccine","type":"ACTIVE_COMPARATOR"},{"label":"Licensed Influenza vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The study is aim to evaluate the immunogenicity and safety with two groups of participants who will received a seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or an active comparator (licensed influenza vaccine","primaryOutcome":{"measure":"Number and Percentage of Seroconverted Participants at 21 Days Post-vaccination","timeFrame":"pre-vaccination (Day 0), 21 days post-vaccination","effectByArm":[{"arm":"GPO Tri Fluvac Vaccine","deltaMin":413,"sd":null},{"arm":"Licensed Influenza Vaccine","deltaMin":216,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":2,"countries":["Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":630},"commonTop":["upper respiratory tract infection","headache","Pyrexia","rhinorrhoea","Diarrhoea"]}}